Drug details
Quillichew ER (methylphenidate hydrochloride extended-release chewable tablets)
type of
QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
This drug may have the following side effects:
- nausea,
- headache,
- palpitations,
- dizziness,
- blurred vision,
- vomiting,
- indigestion,
- tremor,
- fever, and
- nervousness,
- weight loss,
- restlessness,
- dry mouth,
- insomnia,
- anxiety,
- increased sweating,
- abdominal pain,
- irritability,
- rapid heart rate,
- agitation,
- decreased appetite,
- spinning sensation (vertigo),
- mood swings,
- aggression,
- increased blood pressure.
The following drugs are related to Quillichew ER, either as a replacement or used together:
- Adderall (amphetamine, dextroamphetamine mixed salts)
- Adderall XR (amphetamine, dextroamphetamine mixed salts)
- Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablets)
- Strattera (atomoxetine hcl)
- Kapvay (clonidine hydrochloride extended-release tablets)
- Concerta (methylphenidate extended-release tablets)
- Focalin XR (dexmethylphenidate hydrochloride)
- Focalin (dexmethylphenidate hydrochloride)
- Tofranil (imipramine)
- Tofranil-PM (imipramine pamoate)
- Vyvanse (lisdexamfetamine dimesylate)
- Metadate CD (methylphenidate hydrochloride extended-release capsules)
- Metadate ER (methylphenidate hydrochloride extended release tablet)
- Ritalin (methylphenidate hcl)
- Quillivant XR (methylphenidate hydrochloride extended release oral suspension, cii)
- Ritalin LA (methylphenidate hydrochloride extended-release capsules)